These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22202242)

  • 1. [Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Shibata M; Maeda T; Ueda Y; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1930-2. PubMed ID: 22202242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2252-4. PubMed ID: 21224538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Shibata M; Gonda K; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1791-3. PubMed ID: 23267888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy].
    Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S; Shiono M
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2265-7. PubMed ID: 19106591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Indoleamine 2, 3-dioxygenase activity during neoadjuvant chemotherapy in patients with breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1578-80. PubMed ID: 24393854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer].
    Sakurai K; Matsuo S; Enomoto K; Tani M; Kitajima A; Amano S
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1991-3. PubMed ID: 20037301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1590-2. PubMed ID: 24393858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indoleamine 2,3-Dioxygenase Activity during Letrozol Therapy for an Elderly Breast Cancer Patient].
    Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):892-895. PubMed ID: 29066687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indoleamine 2,3-Dioxygenase Activity in Intracystic Breast Tumors].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Enomoto K; Hirano T; Tomita R; Gonda K
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1295-1297. PubMed ID: 27760965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indoleamine 2,3-dioxygenase activity in breast cancer patients with local recurrence or distant metastases].
    Sakurai K; Fujisaki S; Suzuki S; Nagashima S; Maeda T; Tomita R; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1304-6. PubMed ID: 25335725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Hirano T; Enomoto K; Tomita R; Gonda K
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1233-1236. PubMed ID: 27760945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].
    Suzuki Y; Sakurai K; Adachi K; Kubota H; Suzuki S; Takei S; Hara Y; Enomoto K; Hirano T; Makishima M
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1495-1497. PubMed ID: 30382056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor Resistant Metastatic Breast Cancer].
    Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):886-888. PubMed ID: 29066685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
    Sakurai K; Fujisaki S; Suzuki S; Adachi K; Nagashima S; Masuo Y; Tomita R; Gonda K; Enomoto K; Amano S; Matsuo S; Umeda N
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1225-7. PubMed ID: 26489554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indoleamine 2,3-Dioxygenase Activity during I131-Radioisotope Therapy for Metastatic Thyroid Cancer].
    Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Tomita R; Gonda K; Hirano T; Enomoto K
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1259-61. PubMed ID: 26489565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
    Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
    Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
    J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients.
    Huttunen R; Syrjänen J; Aittoniemi J; Oja SS; Raitala A; Laine J; Pertovaara M; Vuento R; Huhtala H; Hurme M
    Shock; 2010 Feb; 33(2):149-54. PubMed ID: 19487973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.